首页 | 本学科首页   官方微博 | 高级检索  
     

宫颈癌紫杉醇脂质体新辅助化疗近期疗效观察
引用本文:谢守珍,刘宏,陈枝岚,宋成文,王晶. 宫颈癌紫杉醇脂质体新辅助化疗近期疗效观察[J]. 中华肿瘤防治杂志, 2011, 18(6): 460-462
作者姓名:谢守珍  刘宏  陈枝岚  宋成文  王晶
作者单位:1. 广州军区武汉总医院妇产科,湖北,武汉,430070
2. 广州军区武汉总医院医务部,湖北,武汉,430070
摘    要:目的:比较注射用紫杉醇脂质体与紫杉醇注射液在宫颈癌新辅助化疗中的临床效果和病理反应。方法:选取有可比性的55例宫颈癌患者,随机进入治疗组和对照组。治疗组35例应用紫杉醇脂质体,每次剂量135 mg/m2;对照组20例应用紫杉醇每次剂量135 mg/m2。两组均联合卡铂化疗,每3周重复1次为1个周期,共2个周期,3周后评价局部反应,随后手术;并对两组术后病理和毒副反应进行分析。结果:治疗组局部反应总有效率为85.7%,对照组总有效率为55.0%,差异有统计学意义,P<0.05;术后病理检查治疗组淋巴结转移1例(2.9%),对照组淋巴结转移5例(25.0%),差异有统计学意义,P<0.05;局部反应越好的病例,其病理反应越明显,χ2=54.76,P<0.05。皮疹和周围神经炎发生率,治疗组明显低于对照组,差异有统计学意义,P<0.05。结论:紫杉醇酯质体联合卡铂的新辅助化疗,提高了局部晚期宫颈癌患者的局部反应及病理反应,提高手术切除的机会,其化疗毒副反应明显低于紫杉醇,临床应用安全可靠。

关 键 词:宫颈肿瘤/药物疗法  抗肿瘤药/治疗应用  紫杉酚/治疗应用

Clinical and pathological study of neoadjuvant chemotherapy with paclitaxel liposome in bulky cervical cancer
XIE Shou-zhen,LIU Hong,CHEN Zhi-lan,SONG Cheng-wen,WANG Jing. Clinical and pathological study of neoadjuvant chemotherapy with paclitaxel liposome in bulky cervical cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2011, 18(6): 460-462
Authors:XIE Shou-zhen  LIU Hong  CHEN Zhi-lan  SONG Cheng-wen  WANG Jing
Affiliation:XIE Shou-zhen,LIU Hong,CHEN Zhi-lan,SONG Cheng-wen,WANG Jing Wuhan General Hospital of Guangzhou Military Command,Wuhan 430070,P.R.China
Abstract:OBJECTIVE:To compare the efficacy and toxicity of paclitaxel liposome and traditional paclitaxel injection in the bulky cervical cancer.METHODS:Totally 55 patients with comparable bulky cervical cancer were randomized into experimental group and control group.The experimental group including 35 patients received paclitaxel liposome 135 mg/m2 each cycle,and the control group including 20 patients received paclitaxel 135 mg/m2 each cycle.Both groups combined with carboplatin per cycle every 3 weeks.The effica...
Keywords:cervical neoplasms/drug therapy  antineoplastic agents/therapllic use  paclitaxel/therapuic use  
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号